Actual issues in cardiovascular endocrinology

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Article deals with the proЫems of cardiovascular endocrinology. Throughout medical science, there are very few areas where Ьasic science investigation links as closely to clinical observations and therapy as in the field of cardiovascular endocrinology. Cardiovascular abnormalities are not only early symptoms of endocrine diseases, but they are the leading cause of patients' death. Results of fundamental investigations in endocrinology are being widely used in cardiology. Further study of endocrine disease will favour successful treatment and prevention of cardiovascular diseases.

About the authors

N. А. Yoitskii

I. Р. Pavlov State Medical University

Author for correspondence.
Email: shabanov@mail.rcom.ru

Академик РАМН

Russian Federation, St. Petersburg

Y. V. Blagosklonnaja

I. Р. Pavlov State Medical University

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

Е. V. Shlokhto

Cardiovascular diseases, endocrinology, treatment, prevention

Email: shabanov@mail.rcom.ru

член-корреспондент РАМН

Russian Federation, St. Petersburg

Е. N. Grineva

Email: shabanov@mail.rcom.ru
Russian Federation

V. В. Bregovskii

Email: shabanov@mail.rcom.ru
Russian Federation

А. Y. Babenko

Email: shabanov@mail.rcom.ru
Russian Federation

References

  1. Adler А., Stevens R., Neil А. et al. UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes // Diabetes Care. 2002. Vol. 25. Р. 894-899.
  2. Aljada А., Ghanim Н, Mahanty Р. et al. Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factors and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and concentrations // Ат. J. Clin. Nutr. 2004. Vol. 80. Р. 51-57.
  3. American association of clinical endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome // Endocr. Pract. 2005. Vol. 11. Р. 126-134.
  4. American Diabetes Association. Consensus statement: Peripheral arterial disease in people with diabetes // Clin. Diab. 2004. Vol. 22. P. 181-189.
  5. Auer J., Scheibner P, Mische T. et al. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. // Am. Heart. J. 2001. Vol. 142. P. 83 8-842.
  6. Biondi B., Palmieri E. A., Lombardi G. et al. Effects of subclinical thyroid dysfunction on the heart /7 Ann. Intern. Med. 2002. Vol. 137. P. 904-914.
  7. Burggraaf J., Lalezari S., Emeis J. J. etal. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol // Thyroid. 2001. Vol. 11. № 2. P. 153-160.
  8. Buse J. B., Polonsky K. S., Burant C. F. Type 2 Diabetes Mellitus. Ch. 29 H In Section 8 - Disorders of Carbohydrate and Lipid Metabolism Larsen: Williams. Textbook of Endocrinology, 10th ed.
  9. Caraccio N., Ferrannini E., Monzani F et al. Effect of levothyroxine replacement on lipid profile and intimamedia thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study //J. Clin. Endocrinol. Metab. 2002. Vol. 89. P. 2099-2106.
  10. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2003. Atlanta, Georgia: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2004. Available at: http://www. cdc. gov/diabetes/pubs/ factsheet, htm. Accessed August 30, 2005.
  11. Colao A., Ferone D., Marzullo P., Lombardi G. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management // Endocr. Rev. 2004. Vol. 25. P. 102-152.
  12. Dandona P, Chaudhuri A., Granim H. et al. Effect of hyperglycemia and insulin in acute coronary syndrome //Am. J. Cardiol. 2007. Vol. 99. P. 12H-19H
  13. De Leo V., la Marca A., Petraglia F. etal. Insulin-lowering agents in the management of polycystic ovary syndrome // Endocr. Rev. 2003. Vol. 24. P. 633-667.
  14. Dhindsa S., Tripaty D., Mohanty P. et al. Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear nuclear factors - кВ in mononuclear cells П Metabolism. 2004. Vol. 53. P. 330-334.
  15. EckelR H„ Kahn R, Robertson R M„ Rizza RA. Preventing cardiovascular disease and diabetes: A call to action from the American Diabetes Association and the American Heart Association // Diabetes Care. 2006. Vol. 29. P. 1697-1699.
  16. Fuller J. H. Coronary - heart-disease risk and impaired glucose tolerance. The Whitehall Study // Lancet. 1980. Vol. 1. P. 1373-1376.
  17. Fur nary A. P, Braithwaite S. S. Effects of outcome on in-hospital transition from intravenous insulin infusion to subcutaneous therapy // Am. J. Cardiol. 2006. Vol. 98. P. 557-564.
  18. Ghanim H., Aljada A., Hofineyer D. Circulating mononuclear cells in the obese are in a proinflammatory state // Cumulation. 2004. Vol. 110. P. 1564-1571.
  19. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text // Eur. Heart J. 2007. Vol. 9 (suppl. С). P. C3-C74.
  20. Gustafsson L, Kistorp C., James M. K. Unrecognized glycometabolic disturbance as measured by hemoglobin Ale is associated with a poor outcome after acute myocardial infarction //Am. Heart J. 2007. Vol. 154. P. 470-476.
  21. Haffner S. M„ Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and prior myocardial infartion //NEJM. 1998. Vol. 339. P. 229-234.
  22. Howard В. V., Kuller L., Langer R et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: The Women's Health Initiative Observational Study // Circulation. 2005. Vol. 111. P. 1462-1470.
  23. Klein L Endocrine Disorders and Cardiovascular Disease. Ch. 79 // In Part X - Cardiovascular Disease and Disorders of Other Organs,. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed.
  24. Levin and O’Neal’s: The diabetic foot / Ed. Bowker J. and Pfeifer M. 2001. Ch. 28. P. 607-635.
  25. Margolis К I., Bonds D. E„ Rodabough R J. et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial // Diabetologia. 2004. %l. 47. P. 1175-1187.
  26. Mohandas B., Mehta J. Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease H Cur. Opin. Cardiol. 2007. Vol. 22. P. 434-442.
  27. Morin-Papunen L, Rautio K, Ruokonen A. et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome // J. Clin. En¬docrinol. Metab. 2003. Vol. 88. P. 4649-4654.
  28. Nathan D. M., Cleary P. A., Backlund J. Y. Diabetes Control and Complications Trial / Epidemiology of Di-abetes Interventions and Complications (DCCT/ED1C) Study Research Group et al: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes // N. Engl. J. Med. 2005. Vol. 353. P. 2643-2653.
  29. Prenitce R. L., Langer R. D., Stefanick M. L. et al. Combined analysis of women's health initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease // Am. J. Epidemiol. 2006. Vol. 163. P. 589-599.
  30. Razvi S., Igoe L., Keeka G. et al. The beneficial effect of L-thyroxine on cardiovascular risk factors, endotelial function and quality of life in subclinical hypothyroidism: a randomized crossover trial H J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 1715-1723.
  31. Rodondi N., Anjesky D., Vittinghoff Е. Subclinical hypothyroidism and the risk of coronary heart diseases: meta-analysis // Am. J. Med. 2006. Vol. 119. Р. 541-551.
  32. Stefanick M., Cochrane В., Hsia J. et аl. The women's health initiative postmepausal hormone trials: overview and baseline characteristics of participants //Ann. Epidemiol. 2003. Vol. 13. Р. S78-S86.
  33. Vanhorebeek L., Langouche L., van den Berghe G. Tight Blood Glucose Control with Insulin in the ICUF acts and Controversies // Chest. 2007. Vol. 132. Р. 268-278.
  34. VinikA. l., Maser R. Е., Mitchell В. D., Freeman R Diabetic autonomic neuropathy // Diabetes Care. 2003. Vol. 26. Р. 1553-1579.
  35. Wilson М, Weinreb J., Soo Ноо G. W. Intensive insulin therapy in critical care. А review of 12 protocols // Diabetes Care. 2007. Vol. 30. Р. 1005-1011.
  36. Ziegler D., Zentai С., Perz S. et аl. KORA Study Group. Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunc¬tion in the general population // Ехр. Clin. Endocrinol. Diab. 2006. Vol. 114. Р. 153-159.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.